Consequently, attenuating the activity of inflammatory mediators in an IL-1β-rich microenvironment may be an effective therapeutic approach to prevent tissue degradation and alveolar bone loss associated with periodontitis, particularly during orthodontic treatment. The gene discussed is IL1B; the disease is periodontitis.